Search company, investor...

Founded Year

2002

Stage

Dead | Dead

Total Raised

$104.45M

About VaxInnate Corporation

VaxInnate is a privately-held biotechnology company in Cranbury, NJ that is developing a technology platform for use in developing novel and proprietary vaccines. VaxInnate's vaccines focus on infectious diseases, including seasonal and pandemic flu, dengue, and Clostridium difficile. VaxInnate's technology has the potential to dramatically improve the potency, manufacturing capacity and cost-effectiveness of vaccines. VaxInnate has already generated positive Phase 1, and in some instances Phase 2, clinical data for its monovalent seasonal vaccine components as well as its prototypic pandemic vaccines. These vaccines have demonstrated excellent potency in the elderly population-a group that is typically less responsive to influenza vaccines.

Headquarters Location

3 Cedar Brook Drive Suite 1

Cranbury, New Jersey, 08512,

United States

609-860-2260

Loading...

Loading...

VaxInnate Corporation Patents

VaxInnate Corporation has filed 18 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/1/2015

9/20/2016

Animal viral diseases, Zoonoses, Psychiatric diagnosis, Neurological disorders, Syndromes

Grant

Application Date

12/1/2015

Grant Date

9/20/2016

Title

Related Topics

Animal viral diseases, Zoonoses, Psychiatric diagnosis, Neurological disorders, Syndromes

Status

Grant

Latest VaxInnate Corporation News

08:00 EDT Myeloid Therapeutics Strengthens Senior Team to Support the Expansion of its Manufacturing Capabilities

Aug 23, 2022

News provided by Share this article Share this article CAMBRIDGE, Mass., Aug. 23, 2022 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company harnessing the power of myeloid and innate biology to engineer novel therapies that elicit a broad immune response for cancer and autoimmune diseases, today announced that it has expanded its manufacturing capabilities with the appointments of Jerome Chal, Ph.D., as Vice President, Process Development, and Eric Chapdelaine as Vice President, CMC Operations. "We are thrilled to continue to attract the highest levels of talent to Myeloid, as we expand our manufacturing capabilities to support our clinical-stage cell therapy programs and the advancement of our in vivo cell programming programs into the clinic next year," said Daniel Getts, Ph.D., CEO of Myeloid. "Jerome and Eric bring a diverse set of skills with significant quality and CMC experience at leading companies like Vertex, Alnylam, and Genzyme. As senior leaders, they will provide invaluable stewardship as we advance and expand our pipeline and read out more clinical data. We are thrilled to welcome them to the Myeloid team, and we look forward to their contributions to our technology and the cell therapy field generally." Jerome Chal, Ph.D., Vice President, Process Development Dr. Chal brings to Myeloid over twenty years of experience in the biotechnology industry, with a focus on CMC leadership across multiple therapeutic modalities, including cell and gene therapies, with landmark achievements in the field. Prior to Myeloid, Jerome was Executive Director, Analytical Sciences at Vertex Pharmaceuticals, where he provided strategic leadership to a multi-site and multi-department CMC organization across the T1D, blood disorders and DMD programs, along with end-to-end implementation of all analytical CMC activities from preclinical to pivotal stage. Prior to Vertex, Dr. Chal was Associate Director, Cell and Analytical Development at Semma Therapeutics, where he directed cell, process and assay development programs for cell therapy products based on a proprietary preclinical-stage PSC-based pancreatic islets (SC-islets) platform. Earlier in his career, he held positions of increasing responsibility at Coyne Scientific, IGBMC in Strasbourg, France, and faculty scientist at Brigham and Women's Hospital, Harvard Medical School. Dr. Chal received his MS in Biology-Biochemistey from ENS Paris, Paris 7 University, an MS in Molecular and Cellular Developmental Biology  from Sorbonne University, and a Ph.D. in Stem Cell and Developmental Biology from Sorbonne University/Stowers Institute, Kansas City, MO. Dr. Chal is a decorated scientist with multiple patents and over twenty peer-reviewed publications in the fields of cell and gene therapy. Eric Chapdelaine, Vice President, CMC Operations Mr. Chapdelaine has over twenty years of experience leading Manufacturing, CMC, Quality (QC+QA), Analytical Development, and Regulatory Affairs organizations in cell and gene therapy. Eric has overseen and led IND and NDA filings for multiple products that received approval in the US and EU. Prior to joining Myeloid, Eric was Senior Vice President of Operations at iVexSol, Inc., where he designed and optimized the manufacturing facility layout, flow and associated office space, as well as overseeing the buildout of the cGMP manufacturing facility. Earlier, he was Vice President of Manufacturing at Genprex, Inc., where he was responsible for translating the corporate strategy into supportive strategies for global pharmaceutical manufacturing, packaging, supply chain, logistics and quality control from early product development through global manufacturing for commercial products. He has also held senior positions at Cognate Bioservices, Inc., and Alnylam Pharmaceuticals, where he was responsible for authoring CMC sections for regulatory submissions, IMPD/IND/NDA, for Patisiran and Givosiran, which are the first two RNA interference therapeutics approved for commercialization in the US and EU. Eric started his career in positions within quality control, manufacturing and CMC at Genzyme Corporation, VaxInnate Corporation, and Pfizer, Inc, respectively. Mr. Chapdelaine holds a Bachelor's of Science from the University of Massachusetts at Amherst and a Masters of Science, Chemistry, from Vanderbilt University. About Myeloid Therapeutics Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company harnessing the power of myeloid cell biology to engineer new therapeutic alternatives for patients with cancer and autoimmune diseases. Integrating the fields of RNA biology, immunology, and medicine, the Company's proprietary platform provides clinical solutions that match therapeutic modalities to disease conditions, including use of autologous cell therapies, in vivo cell programming using mRNA, RNA-based gene-editing using RetroT™ and multi-targeted biologics. Myeloid is advancing a broad portfolio of clinical and preclinical candidates designed to enable full immune system responses. Myeloid has entered into strategic partnerships with Prime Medicine and Acuitas and is supported by well-known biotechnology investors. Myeloid is headquartered in Boston, MA. For more information, visit https://www.myeloidtx.com/ . Investor and Media Contact

VaxInnate Corporation Frequently Asked Questions (FAQ)

  • When was VaxInnate Corporation founded?

    VaxInnate Corporation was founded in 2002.

  • Where is VaxInnate Corporation's headquarters?

    VaxInnate Corporation's headquarters is located at 3 Cedar Brook Drive, Cranbury.

  • What is VaxInnate Corporation's latest funding round?

    VaxInnate Corporation's latest funding round is Dead.

  • How much did VaxInnate Corporation raise?

    VaxInnate Corporation raised a total of $104.45M.

  • Who are the investors of VaxInnate Corporation?

    Investors of VaxInnate Corporation include New Leaf Venture Partners, MedImmune Ventures, Canaan Partners, New Jersey Economic Development Authority, Oxford Bioscience Partners and 5 more.

  • Who are VaxInnate Corporation's competitors?

    Competitors of VaxInnate Corporation include FluGen, Immune Design, Sutro Biopharma, Vaxart, Midway Biome and 7 more.

Loading...

Compare VaxInnate Corporation to Competitors

L
Lofarma S.p.A.

Lofarma S.p.A. is a pharmaceutical company focused on the diagnosis and treatment of allergic respiratory diseases. The company develops and markets specific immunotherapies and diagnostic tools for allergies, targeting medical professionals in both private and public healthcare settings. Lofarma's continuous investment in research and development enables innovative approaches to treating a wide range of allergic respiratory conditions. It is based in Italy.

V
Vaxent

Vaxent has developed a StepNovA vaccine for Group A streptococcus

FluGen Logo
FluGen

FluGen is a clinical-stage company focused on improving vaccine efficacy in the biotechnology sector, specifically targeting respiratory diseases. The company's main offering is the development of a supra-seasonal influenza vaccine designed to provide broad immune response and protection against virus drift. FluGen's M2SR Vaccine Platform aims to enhance flu prevention by stimulating mucosal, humoral, and cellular immunity. It was founded in 2007 and is based in Madison, Wisconsin.

Vivaldi Biosciences Logo
Vivaldi Biosciences

Vivaldi Biosciences focuses on the development of vaccines for viral respiratory diseases, operating in the biotechnology and healthcare sectors. The company's main offerings include the development of vaccines that provide protection against epidemic and pandemic viral respiratory diseases, utilizing a technology platform known as Delta NS1. Its vaccines, administered via nasal spray, are designed to rapidly induce interferon, generating protection against viruses entering the nasal passages and activating systemic antibody and cell-based protective immunity. It was founded in 2006 and is based in Fort Collins, Colorado.

S
Savine Therapeutics

The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology.  The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University.  Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com

M
ModiQuest

ModiQuest is a biotechnology company focused on developing novel therapeutics for inflammatory diseases, particularly in the domain of rheumatoid arthritis. The company specializes in using recombinant antibody technology to create therapeutic leads aimed at treating rheumatoid arthritis and other inflammatory conditions. ModiQuest primarily serves the biopharmaceutical industry with its therapeutic leads designed for co-development or outlicensing. It was founded in 2004 and is based in Netherlands.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.